[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Trustees of Dartmouth College\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":543},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,53,73,101,130,153,183,208,242,269,297,320,340,361,378,403,428,476,495,520],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100639845","eating-disorder-dynamic-intervention-100639845",false,"NCT07600671","Eating Disorder Dynamic Intervention","Rapid Innovation of Precision Psychiatry Interventions Using Dynamic Systems Modeling and Ecological Quasi-Experiments","EDDI","Inclusion Criteria:\n\n1. Age 18-70\n2. At least 12 ED behaviors from the same behavioral category in the past 12 weeks (i.e., at least 12 binge eating episodes, at least 12 compensatory behaviors, and\u002For at least 12 instances of dietary restriction)\n3. Ownership of a smartphone\n4. Willingness to complete ecological momentary assessment (EMA) and sensor data collection\n5. Live in the United States\n6. Has a primary care provider or is willing to establish a primary care provider\n\nExclusion Criteria:\n\n1. Inability to fluently speak, read, and write in English\n2. Body mass index \\\u003C 17.5 kg\u002Fm2\n3. Medical complications of ED symptoms requiring immediate treatment\n4. Current ED-focused therapy\n5. Severe psychopathology (i.e., active suicidal ideation, psychosis, bipolar disorder, or substance use disorder) or intellectual disability inhibiting engagement in study protocols","ALL","18 Years","70 Years",{"count":21,"type":22},170,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this study is to develop and test a digital program to help people with eating disorders in their everyday lives. The program uses brief surveys and sensor data collected by smartphones to understand when someone may be at higher risk for behaviors like restricting food, binge eating, or using unhealthy weight control behaviors.",[28,29,30,31,32],"Eating Disorders","Anorexia Nervosa","Bulimia Nervosa","Binge Eating Disorder","Other Specified Feeding or Eating Disorder",[34,35,36,37,38,39,40],"binge eating","eating problem","eating disorder","purging","restriction","weight control behavior","dieting","RECRUITING","2026-06-29",{"date":44,"type":45},"2026-07-01","ACTUAL",{"date":42,"type":45},{"date":48,"type":22},"2030-07-31",{"name":50,"class":51},"Trustees of Dartmouth College","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":52},"100591082","effects-of-social-feedback-on-intracranial-eeg-100591082","NCT06975800","Effects of Social Feedback on Intracranial EEG","Inclusion Criteria:\n\n* Patients must be between 18-65 years of age.\n* Patients must have a diagnosis of refractory epilepsy undergoing intracranial EEG recording for clinical purposes.\n* Patients with a legal guardian will be considered for participation if they are interested and, in the judgment of the research team, they are capable of performing the cognitive tasks required of the study. In those instances, the patient and their legal guardian will both participate in the informed consent process, with the legal guardian signing the consent form.\n\nExclusion Criteria:\n\n* Patient has additional neurological condition (such as stroke or dementia) or a psychiatric condition (such as active psychosis or suicidal ideation) and are deemed inappropriate for the study.\n* Patients are not able to provide informed consent for any reason (e.g. encephalopathic, experiencing a seizure).","65 Years",{"count":61,"type":22},24,[25],"This study aims to assess the impact of social influence on direct neural recordings in human patients undergoing surgical treatment of epilepsy. 24 patients recruited from the Epilepsy Center at Dartmouth Health Medical Center (DHMC) will undergo electrode implantation throughout the brain to localize epileptogenic zones. Patients will be asked to rate their provider's warmth, competence, and other, similar traits associated with care-competency. They will then complete the picture-induced fear and math portions of the multimodal negative affect task (MNAT) during which iEEG is recorded.",[65,66],"Social Influence","Epilepsy",{"date":44,"type":45},{"date":69,"type":45},"2023-04-06",{"date":71,"type":22},"2028-02-28",{"name":50,"class":51},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100642931","digitally-enhanced-peer-doula-model-for-perinatal-patients-with-substance-use-disorder-100642931","NCT07642947","Digitally Enhanced Peer Doula Model for Perinatal Patients With Substance Use Disorder","A Digitally Enhanced Model of Peer Doula Support for Substance Use Disorder and Peripartum Care","EMBRACE","Staff Participant\n\nInclusion Criteria:\n\n1. 18 years of age or older.\n2. Employed by the participating clinic site and identified as care providers and\u002For administrative staff. Clinic roles may include:\n\n   1. Provider (including MD, CNM, DO, PA, NP, nurse, medical assistant, behavioral health clinician, social worker, lactation consultant and\u002For other clinical roles that provide care to patients).\n   2. Peer doulas.\n   3. Administrator (including front desk staff, scheduler, clinic and\u002For team manager).\n   4. Site leadership.\n3. Able to speak English sufficiently to understand the study and, having understood, provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Unwilling or unable to provide consent\n2. Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law; or have pending legal action that could prevent participating in study activities\n\nPatient Participant (Cohort 1 \\& Cohort 2)\n\nInclusion Criteria\n\n1. 18 years of age or older\n2. Patient of the participating site who is eligible to receive prenatal, postpartum, or delivery services\n\n   •Either\n   1. Not currently engaged in the digitally enhanced peer doula model and no prior exposure to the model or less than 30 days exposure to the model if newly enrolled, AND currently pregnant or up to 6 weeks postpartum.\n\n      OR\n   2. Currently engaged in the digitally enhanced peer doula model for more than 30 days, AND currently pregnant or up to one year postpartum\n3. Able to speak English sufficiently to understand the study and, having understood, provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Unable or unwilling to provide consent to participate in study activities\n2. Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law; or have pending legal action that could prevent participating in study activities\n3. Currently unable to engage in the digitally enhanced peer doula model or attend research visits",{"count":82,"type":22},100,"OBSERVATIONAL","The goal of this pilot study is to learn if a digitally enhanced peer doula program for people with perinatal substance use disorders (PSUD) is feasible and acceptable to patients and staff at two clinics.\n\nParticipants will include staff members, such as healthcare providers, recovery support doulas, and administrators, who work at one of the two clinics. It will also include PSUD patients receiving care through the digitally enhanced peer doula program.\n\nParticipants will be asked to complete short surveys and take part in a one-time interview with research staff.\n\nThis study will also explore engagement in perinatal substance use disorder treatment and prenatal and postpartum visits.",[86],"Perinatal Substance Use",[88,89,90],"Peer Doula","Perinatal Substance Use Disorder","Digital Model of Care","NOT_YET_RECRUITING","2026-06-09",{"date":94,"type":45},"2026-06-11",{"date":96,"type":22},"2026-06-01",{"date":98,"type":22},"2027-02-28",{"name":50,"class":51},2,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":52},"100591412","neural-mechanisms-of-interpersonal-expectations-on-negative-affect-100591412","NCT06980090","Neural Mechanisms of Interpersonal Expectations on Negative Affect","Inclusion Criteria:\n\n'Doctors' are recruited from medical students at the Geisel School of Medicine and resident physicians at Dartmouth Hitchcock Medical Center (DHMC).\n\nExclusion Criteria:\n\n* No self-reported current or history of depression, bipolar disorder, or other psychiatric diagnosis\n* No self-reported current seizure disorder (i.e., seizure within past 10 years), or history of stroke or other major neurological diagnosis that can cause cognitive impairment\n* No self-reported current chronic pain, or acute pain within three months of the study period\n* No current migraine disorder (i.e., 15 headache days or more in 1 month)\n* No use of central nervous system-effective medication or other medication for neurological\u002Fpsychiatric treatment\n* No self-reported substance abuse within the last six months\n* No contraindication to MRI or tTIS (e.g., pregnancy, claustrophobia, pacemakers, ear\u002Fcochlear implants, shrapnel injuries, clips, or other ferromagnetic\u002Felectrical objects\u002Fdevices, diagnosed brain abnormality such as tumor, or skin lesions on the scalp.)\n* No contraindications for induced pain (e.g., no heart disease, high blood pressure, heart surgery, heart problems of any kind, severe asthma, respiratory problems of any kind, fibromyalgia, Raynaud's Syndrome or Disease, chronic pain, diabetes)\n* Participants must be capable of performing experimental tasks (e.g., are able to read), are fluent or native speakers of English\n* Participants must be able to tolerate the maximum level of thermal pain stimuli (for thermal stimuli)",true,"55 Years",{"count":110,"type":22},196,[25],"The goal of this clinical trial is to learn whether non-invasive brain stimulation, called transcranial temporal interference stimulation (tTIS), can reduce negative affect, and how expectations shaped by care providers influence these effects.\n\nThe main questions this study aims to answer are: (1)Does active tTIS reduce negative affect more effectively than sham (inactive) tTIS? (2)Do positive treatment expectations enhance the effects compared to negative expectations?\n\nParticipants will: (1) Receive either active or sham tTIS. (2) Be provided with positive or negative messaging regarding treatment effectiveness. (3) Interact with care providers and complete assessments measuring negative affect and physiological responses.",[114,115,116,117],"Negative Affectivity","Non-invasive Brain Stimulation","Placebo Effect","Expectations",[119,120,121,122],"Transcranial temporal interference stimulation","Pain","Fear","Cognitive effort","2026-06-08",{"date":94,"type":45},{"date":126,"type":45},"2025-09-01",{"date":128,"type":22},"2028-03-03",{"name":50,"class":51},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":107,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":52},"100609617","evaluating-the-impact-of-psychotherapeutic-advertising-claims-on-cannabis-purchasing-100609617","NCT07216911","Evaluating the Impact of Psychotherapeutic Advertising Claims on Cannabis Purchasing","Inclusion Criteria:\n\n* Age 21 years or older\n* Current residence in the United States\n* Cannabis use on 1-100 days in the past year\n* Current symptoms of mild to severe depression and\u002For generalized anxiety disorder, assessed by PHQ-8 (score ≥ 5) and GAD-7 (score ≥ 5)\n\nExclusion Criteria:\n\n* Under 21 years of age\n* Not currently residing in the United States","21 Years",{"count":138,"type":22},2000,[25],"In the U.S., legal cannabis is frequently advertised as an effective treatment for mental health problems such as anxiety and depression-particularly online. States that have legalized cannabis have not implemented regulations to address this type of advertising. This project aims to investigate the influence of psychotherapeutic advertising claims (PAC) and mental health warning labels (WL) on online cannabis purchasing behaviors among light-to-moderate cannabis users with symptoms of depression and\u002For anxiety.\n\nThe specific aims are to determine whether PAC increases cannabis purchasing intentions and whether a mental health WL can mitigate this effect. A realistic online cannabis shopping experience will be simulated using the digital Platform for Online Evaluation of Marijuana Marketing and Sales (POEMMS). The study will employ a between-subjects experimental design by randomizing 2,000 participants to one of four online stores that vary in PAC and WL content: (1) a control claims (CC)-only store, (2) a PAC store, (3) a WL store, and (4) a PAC + WL store. Participants will browse and select items as if making real purchases.\n\nAnalyses will examine three primary outcomes to determine the influence of PAC and WL on purchasing behaviors: (1) total milligrams of THC purchased, (2) average potency (%THC) of products, and (3) overall number of products purchased. The long-term objective is to inform evidence-based cannabis policy and regulatory strategies by understanding the impact of cannabis marketing on vulnerable populations.\n\nThis research is relevant to public health by addressing the potential risks associated with misleading cannabis marketing, which may lead to increased use and exacerbation of mental health symptoms among individuals with depression and anxiety. The project leverages a multidisciplinary team with expertise in addiction, mental health, epidemiology, and digital health technology. The findings have the potential to inform the development of targeted interventions and policies to reduce harms associated with cannabis advertising-ultimately contributing to better health outcomes and more effective regulation.",[142,143,144],"Anxiety","Depression","Cannabis Use","2026-05-19",{"date":147,"type":45},"2026-05-22",{"date":149,"type":45},"2026-04-15",{"date":151,"type":22},"2027-06-30",{"name":50,"class":51},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":107,"sex":17,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":52},"100640887","regular-growth-monitoring-rgm-of-young-children-in-guinea-bissau-100640887","NCT07584395","Regular Growth Monitoring (RGM) of Young Children in Guinea-Bissau","Pilot Study to Assess the Benefits and Sustainability of Regular Growth Monitoring (RGM) of Young Children in Villages in Guinea-Bissau","Inclusion Criteria:\n\n* Children aged 6 months to 5 years residing in one of the two selected villages in Guinea-Bissau\n* Caregiver willing to enroll the child in the study (verbal consent provided)\n* Caregiver can provide birth certificate or documentation of child's age\n* Child does not have severe acute malnutrition (SAM) at the baseline assessment\n\nExclusion Criteria:\n\n* Children diagnosed with severe acute malnutrition (SAM) at baseline (these children will be referred to the local malnutrition clinic)\n* Children whose caregivers do not wish to participate","6 Months","5 Years",{"count":163,"type":22},400,[25],"Wasting (severe thinness) is a common and serious problem among young children in rural Guinea-Bissau. Community Health Agents (CHAs) can help prevent malnutrition by regularly measuring children's growth and advising families on nutritious local foods. However, this practice is not consistently implemented.\n\nThis pilot study will test whether implementing Regular Growth Monitoring (RGM) by CHAs every month is feasible and effective in reducing malnutrition among children aged 6 months to 5 years in two rural villages. Investigators will also compare three methods for measuring mid-upper arm circumference (MUAC), which is used to detect malnutrition: the standard WHO tape measure, a photograph of the arm, and a simple bracelet. The goal is to identify which method is easiest for CHAs to use reliably.\n\nBaseline and final measurements will be taken in both villages. One village will receive the monthly RGM intervention first, followed by the second village. Families will also be asked about their experiences with the program through brief questionnaires.",[167,168],"Severe Acute Malnutrition","Moderate Acute Malnutrition (MAM)",[170,171,172,173,174],"Childhood malnutrition","Growth monitoring","Guinea-Bissau","Wasting","Mid-upper arm circumference","2026-05-07",{"date":177,"type":45},"2026-05-13",{"date":179,"type":22},"2026-05-02",{"date":181,"type":22},"2026-12",{"name":50,"class":51},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100633568","manipulating-social-percepts-during-fmri-100633568","NCT07528378","Manipulating Social Percepts During fMRI","Manipulating Social Percepts With Real-Time fMRI","Inclusion Criteria:\n\n* willingness and availability to come for a total of 6 MRI scan sessions\n* good fMRI data quality in previous, non-clinical trial study, including low head motion, high vigilance during the task as measured via simultaneous eye tracking, consistent behavioral responses\n\nExclusion Criteria:\n\n* metallic objects in body contraindicated for the MRI scanner\n* history of severe psychiatric or neurological disease\n* currently on medication for a psychiatric condition\n* illicit drug use\n* claustrophobia\n* heavy nicotine or alcohol use\n* prior head injury\n* pregnancy","35 Years",{"count":192,"type":22},10,"This study will investigate the use of real-time fMRI to change how participants perceive social information.",[195],"Healthy Volunteers",[197,198,199],"individual differences","social perception","fMRI","2026-04-09",{"date":202,"type":45},"2026-04-14",{"date":204,"type":22},"2026-09-01",{"date":206,"type":22},"2027-05-01",{"name":50,"class":51},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":4},"100588854","implementation-of-a-just-in-time-adaptive-intervention-for-adolescent-anxiety-100588854","NCT06946823","Implementation of a Just-In-Time Adaptive Intervention for Adolescent Anxiety","Community-Engaged Design and Implementation of a Just-In-Time Adaptive Intervention (JITAI) to Improve Adolescent Anxiety in Rural Populations","Inclusion Criteria:\n\n* Adolescent (age 13-17 years old)\n* New Hampshire resident\n* Fluency in English\n* Able to provide assent\n* At least mild (≥5) anxiety based on the GAD-7 assessment\n\nExclusion Criteria:\n\n* Under 13 years old\n* Over 17 years old\n* Not a New Hampshire resident\n* Unable to provide assent\n* Less than mild (\\\u003C5) anxiety based on the GAD-7 assessment","13 Years","17 Years",{"count":218,"type":22},50,[25],"The goal of this clinical trial is to evaluate a smartphone based just-in-time adaptive intervention (JITAI) tool to deliver somatic behavioral recommendations for anxiety management among youth. The main questions it aims to answer are:\n\n* Is the JITAI tool acceptable among the adolescent study population?\n* Is the JITAI tool feasible to deliver to the adolescent study population?\n* Does the study support preliminary efficacy of the JITAI tool among the adolescent study population?\n\nThe tool will be pilot-tested among a sample of 50 rural adolescents experiencing elevated anxiety levels who will be randomly assigned to the JITAI tool or a waitlist control, for a treatment period of 3 months.\n\nParticipants will be asked to:\n\n* Use the smartphone based JITAI tool which will deliver somatic behavioral recommendations intended to manage anxiety levels for a treatment period of 3 months\n* Respond to the tool's prompts on a daily basis and follow the delivered behavioral recommendations\n* Complete anxiety and interoception assessments at study start, study end (3 months), and one-month follow-up\n* Complete usability and user experience instruments at study end (3 months)",[142,222,223],"Anxiety Disorders","Anxiety Disorder of Childhood",[142,225,226,227,228,229,230,231,232,233],"Just-In-Time Adaptive Intervention","Smartphone","Behavioral Health","Community-Engaged Research","Adolescents","Rural","Digital Intervention","Participatory Design","Somatic","2026-04-01",{"date":236,"type":45},"2026-04-02",{"date":238,"type":22},"2027-01",{"date":240,"type":22},"2027-05",{"name":50,"class":51},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":256,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":52},"100600889","table-top-water-pitcher-to-reduce-arsenic-exposure-among-well-users-in-new-hampshire-100600889","NCT07103356","Table-Top Water Pitcher to Reduce Arsenic Exposure Among Well Users in New Hampshire","Developing a Hybrid Type 1 Effectiveness-Implementation Randomized Controlled Trial to Test a Table-Top Water Pitcher to Reduce Arsenic Exposure in Northern New England","Inclusion Criteria:\n\n* Age 18 years or older\n* NH resident living in Merrimack or Belknap county\n* Use a private water system as primary drinking water source\n* Water arsenic \\>5 micrograms\u002FL upon testing\n* Confirm would be primary person in home maintaining the provided pitcher filter\n\nExclusion Criteria:\n\n* Use or plan to use a mitigation strategy to reduce exposure to arsenic-contaminated drinking water in the next 12 weeks",{"count":5,"type":22},[25],"The goals of this clinical trial are to:\n\n1. gather preliminary data on the effectiveness of a table-top water pitcher filtration system in reducing arsenic exposure among individuals using private wells with elevated (\\>5 μg\u002FL) arsenic concentrations, and\n2. identify the factors influencing implementation of the filter intervention (uptake and sustainability) and barriers and facilitators to its use.\n\nThe main questions it aims to answer are:\n\nDo water and urinary arsenic concentrations change from baseline to Week 4 of the water pitcher intervention?\n\nAre changes in arsenic concentrations maintained during the eight-week sustainability period?\n\n* Which factors facilitate or impede uptake, use, and sustainability of the intervention?\n* Are household income and\u002For home ownership associated with sustained filter use?\n\nParticipants will:\n\n* Receive a free 12-cup water filter pitcher and cartridge replacements\n* Use the pitcher filtration system, including replacement of filter cartridges, per manufacturer recommendations\n* Collect and mail water and urine samples at baseline, 4 weeks, and 12 weeks\n* Complete online questionnaires at baseline, 4 weeks, and 12 weeks",[253,254,255],"Arsenic Poisoning","Environmental Exposure","Water-Related Diseases",[257,258,259,260],"Arsenic","Private Well","Environmental Health","Filter","2026-03-20",{"date":263,"type":45},"2026-03-24",{"date":265,"type":45},"2026-02-24",{"date":267,"type":22},"2027-08-31",{"name":50,"class":51},{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":296},"100627907","do-video-recordings-of-multidisciplinary-clinics-improve-quality-of-life-for-people-with-als-and-their-caregivers-100627907","NCT07454733","Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?","Comparing the Impact of Video Integration to Traditional Amyotrophic Lateral Sclerosis Visit Communication on Patient and Caregiver Quality of Life","VITALS","Inclusion Criteria for People with ALS:\n\n* Diagnosis of ALS by either El- Escorial or Gold Coast Criteria\n* ≥18 years of age\n* Plan to attend MDC visits for 12 months\n* Speak English or Spanish\n* Presence of a caregiver (defined as someone who assists with care) who is also participating in the VITALS trial\n* Projected life expectancy of at least 12 months as determined by the site investigator.\n\nExclusion Criteria for People with ALS:\n\n* Unable or unwilling to provide informed consent or follow study procedures\n* Significant cognitive impairment, clinical dementia, or unstable psychiatric illness (including, but not limited to, psychosis, active suicidal ideation, suicide attempt, or untreated major depression) as determined by the site investigator\n* Current pregnancy based on participant self-report;\n* Unable to access the internet;\n* Do not have access to a personal or shared email and are not interested in creating a personal or shared email;\n* Do not wish to create a patient portal account, if they do not already have one;\n* Uncorrected hearing or visual impairment that would impair the ability to view video recordings;\n* Incarcerated.\n\nInclusion Criteria for Caregivers:\n\n* Agree to their identified role as a caregiver of a patient with ALS participating in the VITALS trial;\n* Speak English or Spanish;\n* ≥18 years of age.\n\nExclusion Criteria for Caregivers:\n\n* Unable or unwilling to provide consent or follow study procedures;\n* Unable to access the internet;\n* Do not have access to a personal or shared email and are not interested in creating a personal or shared email;\n* Uncorrected hearing or visual impairment;\n* Professional caregiver for the patient;\n* Incarcerated.",{"count":278,"type":22},800,[25],"Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. The gold standard of care for people with ALS is multidisciplinary clinics (MDC). In these multidisciplinary clinics, which occur every 3 to 4 months, people with ALS see up to 12 different healthcare providers (e.g., speech therapy, physical therapy, the ALS doctor). These clinics can last from three to five hours, and across these three to five hours people with ALS and their caregivers receive a lot of information that is critical to the care and quality of life for people with ALS. However, this information can be difficult to remember given the large amount of information that is conveyed. The current standard for providing take-home information about the visit is to provide patients with a written after-visit summary and access to their doctor's notes about the visit, typically through the patient portal. This study tests whether providing participants with video recordings of their MDC visits improves their quality of life and the quality of life of their caregivers. The study will enroll 400 pairs of people with ALS and their caregivers from eight different sites in the United States. Half of the participants in the study will receive their after-visit summary notes (the NOTES condition) and the other half of the participants will receive both their summary notes, but will also receive video recordings of their MDC visits that they can watch on their own at home (the VIDEO condition). The study will last for 12 months, with participants receiving NOTES or VIDEO at each of their regularly-scheduled MDCs during the 12 months. The study will test whether caregiver and patient participants in the VIDEO condition experience better quality of life than those in the NOTES condition at 1 month, 6 months, and 12 months from study enrollment. The results of this study will help determine what is the most effective approach to communicating MDC information to people with ALS and their caregivers.",[282],"Amyotrophic Lateral Sclerosis (ALS)",[284,285,286,287,288],"amyotrophic lateral sclerosis (ALS)","Open Notes","Open Recordings","video recording","after-visit summaries","2026-03-03",{"date":291,"type":45},"2026-03-06",{"date":96,"type":22},{"date":294,"type":22},"2029-10-01",{"name":50,"class":51},7,{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":52},"100412123","context-interventions-social-modeling-and-initial-treatment-experience-100412123","NCT04646460","Context Interventions: Social Modeling and Initial Treatment Experience","Inclusion Criteria:\n\n* No current psychiatric or major neurological diagnosis\n* No reported substance abuse within the last six months\n* Capable of performing experimental tasks (e.g., are able to read, able to cooperate with fMRI examination)\n* Fluent or native speakers of English\n* No current or recent history of pathological pain or reported neurological disorders\n* Abstained from alcohol and substance use for 48 hours\n* Provided informed consent\n* Passed fMRI screening test\n\nExclusion Criteria:\n\n* Current presence of pain\n* Current or past history of primary psychiatric disorder\n* Current or past history of psychoactive substance abuse or dependence\n* Dementias\n* Movement disorders except familial tremor\n* CNS infection\n* CNS vasculitis, inflammatory disease or autoimmune disease\n* CNS demyelinating disease (e.g. multiple sclerosis)\n* Space occupying lesions (mass lesions, tumors)\n* Congenital CNS abnormality (e.g. cerebral palsy)\n* Seizure disorder\n* History of closed head trauma with loss of consciousness\n* History of cerebrovascular disease (stroke, TIAs)\n* Abnormal MRI (except changes accounted for by technical factors or UBOs)\n* Neuroendocrine disorders (e.g., Cushings disease)\n* Uncorrected hypothyroidism or hyperthyroidism\n* Current or past history of cancer\n* Recent history (within two years) of myocardial infarction, severe cardiovascular disease, or currently active cardiovascular disease (e.g. angina, cardiomyopathy)\n* Uncontrolled hypertension or hypotension\n* Chronic pain syndromes\n* Chronic fatigue syndromes\n* Subjects unable to tolerate the scanning procedures (e.g., claustrophobia)\n* Prior treatment within the last month with any of the following: antidepressants, mood stabilizers, glucocorticoids, opiates\n* Prior treatment with any of the following: antipsychotics, isoniazid, centrally active antihypertensive drugs (e.g. clonidine, reserpine)\n* Metal in body or prior history working with metal fragments (e.g., as a machinist)\n* Pregnancy\n* Any other contraindications for MRI examination (e.g., metallic implants such as pacemakers, surgical aneurysm clips, or known metal fragments embedded in the body)\n* Claustrophobia",{"count":304,"type":22},120,[25],"In this experiment, the investigators study the brain pathways underlying several promising context interventions that enhance the strength of placebo effects. Specifically, the investigators examine the separate and joint effects of two of the most powerful context interventions: Social modeling-observing someone else being effectively treated-and prior treatment success or failure experiences. Participants will be randomized into 4 groups (Social modeling: observed success vs. observed failure and Conditioning: experienced success vs. experienced failure). The objectives are to investigate the placebo effect on pain relief and aversive image stimuli between and within-subjects. Each group will undergo a behavioral induction phase, fMRI placebo test phase, and an identical 3-month follow up fMRI placebo test phase. Follow-up assessment will provide some of the first evidence on predictors of the durability of placebo and context interventions.",[116,120],[309,310,311,120],"Placebo effect","Social modeling","Conditioning","2026-01-14",{"date":314,"type":45},"2026-01-16",{"date":316,"type":22},"2026-12-01",{"date":318,"type":22},"2028-12-01",{"name":50,"class":51},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":23,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":52},"100412631","the-warmth-anticipation-sensation-aversion-and-body-part-imaging-study-100412631","NCT04653064","The Warmth, Anticipation, Sensation, Aversion, and Body-part Imaging Study","Placebo Effects on Anxiety and Pain","WASABI","Inclusion Criteria:\n\n* Subject must be a volunteer with a minimum age of 18 years and must be able and willing to provide written informed consent.\n* If female, the subject must be non-lactating, not pregnant, and using a reliable contraception method.\n* Subject must be able to read and speak English.\n* Subject must be able to understand and follow the instructions of the investigator and understand all screening questionnaires.\n* Subject must have no current or recent history of pathological pain.\n* Subject must have abstained from alcohol and substance use for 48 hours.\n* Subject must pass all fMRI screening tests.\n\nExclusion Criteria:\n\n* If female, pregnancy.\n* Inability to tolerate the scanning procedures (e.g., claustrophobia).\n* Metal in body or prior history working with metal fragments (e.g., as a machinist).\n* Inability to tolerate heat pain applied to the forearm.\n* Reporting temporary abnormal levels of pain.\n* Allergic response to the exfoliating cream.\n* Current presence of pain.\n* Current or past history of psychoactive substance abuse or dependence.\n* Dementias.\n* Movement disorders except familial tremor.\n* CNS infection.\n* CNS vasculitis.\n* Inflammatory disease or autoimmune disease.\n* CNS demyelinating disease (e.g. multiple sclerosis).\n* Space occupying lesions (mass lesions, tumors).\n* Congenital CNS abnormality (e.g. cerebral palsy).\n* Seizure disorder.\n* History of closed head trauma with loss of consciousness.\n* History of cerebrovascular disease (stroke, TIAs).\n* Abnormal MRI (except changes accounted for by technical factors or UBOs.\n* Neuroendocrine disorders (e.g., Cushings disease).\n* Uncorrected hypothyroidism or hyperthyroidism.\n* Current or past history of cancer.\n* Recent history (within two years) of myocardial infarction, severe cardiovascular disease, or currently active cardiovascular disease (e.g. angina, cardiomyopathy).\n* Uncontrolled hypertension or hypotension.\n* Chronic pain syndromes.\n* Chronic fatigue syndromes.\n* A history of neurologic disease or neuropathic pain.\n* Prior treatment within the last month with any of the following: antidepressants, mood stabilizers, glucocorticoids, opiates.\n* Prior treatment with any of the following: antipsychotics, isoniazid, centrally active antihypertensive drugs (e.g. clonidine, reserpine).\n* Any other contraindications for MRI examination (e.g., metallic implants such as pacemakers, surgical aneurysm clips, or known metal fragments embedded in the body).\n* Current treatment for psychiatric disorders including mood, anxiety, substance abuse, attention-deficit\u002Fhyperactivity disorder (ADHD), psychosis.\n* Neurological disorders (e.g., taking dopamine agonists for Parkinson's) Cardiovascular disease or medication (e.g., taking ACE (angiotensin-converting-enzyme) inhibitors for cardiac remodeling).\n* Frequent smoking (\\> 5 cigarettes \u002F day).\n* Frequent alcohol use (\\> 14 drinks \u002F week).\n* Frequent migraines (\\> 5 \u002F month on average).",{"count":329,"type":22},150,[25],"This functional magnetic-resonance imaging study of the brain will feature a within-subject crossover design to investigate the effects of a placebo cream on painful thermal stimulation rendered upon eight body sites. The investigators aim to 1.) improve the understanding of how the brain represents thermal pain responses somatotopically (i.e., across different body-sites) 2.) to test these brain representations with and without the presence of a pain-targeted placebo intervention, and 3.) to examine how these brain representations change prior to vs. during the delivery of thermal pain. They predict that placebo cream will downregulate the intensity of aversive brain activity representations, and to a lesser degree, sensation and somatotopic representations, both prior to and during painful thermal stimulation.",[120],"2026-01-12",{"date":312,"type":45},{"date":336,"type":45},"2021-03-19",{"date":338,"type":22},"2026-12-26",{"name":50,"class":51},{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":52},"100413861","individual-differences-in-placebo-analgesic-effects-100413861","NCT04669093","Individual Differences in Placebo Analgesic Effects","Person by Situation Interaction: Matching Suggestions to Participants' Motivational Styles","Inclusion Criteria:\n\n* Healthy participants\n* Dominant promotion focus or dominant prevention focus (based on our screening)\n\nExclusion Criteria:\n\n* Currently or recently suffered from chronic pain (based on screening)\n* Cannot tolerate heat pain applied to the forearm, based on a calibration task at the beginning of the experiment",{"count":348,"type":22},60,[25],"This study examines the effects of placebo suggestions tailored to match or mismatch individual participants' motivational styles-an issue of person-situation 'fit' with important effects in public health settings, but which has been ignored in past research.",[352],"Healthy","2025-12-02",{"date":355,"type":45},"2025-12-09",{"date":357,"type":22},"2026-09-30",{"date":359,"type":22},"2027-12-31",{"name":50,"class":51},{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":368,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":375,"leadSponsor":377,"locationsCount":52},"100412460","early-phase-1-the-role-of-the-opioid-system-in-placebo-effects-on-pain-and-social-rejection-100412460","NCT04650841","The Role of the Opioid System in Placebo Effects on Pain and Social Rejection","Inclusion Criteria:\n\n* Adults aged 18-55 years\n* No current psychiatric or major neurological diagnosis\n* No reported substance abuse within the last six months\n* Are capable of performing experimental tasks (e.g., are able to read, able to cooperate with fMRI examination)\n* Are fluent or native speakers of English\n* No current or recent history of pathological pain or reported neurological disorders.\n* Having abstained from alcohol and substance use for 48 hours\n* Passed fMRI safety screener\n* Experienced a recent unwanted breakup of a romantic relationship\n\nExclusion Criteria:\n\n* Current presence of pain\n* Current or past history of primary psychiatric disorder\n* Current or past history of psychoactive substance abuse or dependence\n* Dementias\n* Movement disorders except familial tremor\n* CNS infection\n* CNS vasculitis, inflammatory disease or autoimmune disease\n* CNS demyelinating disease (e.g. multiple sclerosis)\n* Space occupying lesions (mass lesions, tumors)\n* Congenital CNS abnormality (e.g. cerebral palsy)\n* Seizure disorder\n* History of closed head trauma with loss of consciousness\n* History of cerebrovascular disease (stroke, TIAs)\n* Abnormal MRI (except changes accounted for by technical factors or UBOs)\n* Neuroendocrine disorder (e.g., Cushings disease)\n* Uncorrected hypothyroidism or hyperthyroidism\n* Current or past history of cancer; Recent history (within two years) of myocardial infarction, severe cardiovascular disease, or currently active cardiovascular disease (e.g. angina, cardiomyopathy)\n* Uncontrolled hypertension or hypotension\n* Chronic pain syndromes\n* Chronic fatigue syndromes\n* Subjects unable to tolerate the scanning procedures (e.g., claustrophobia)\n* Prior treatment within the last month with any of the following: antidepressants, mood stabilizers, glucocorticoids, opiates\n* Prior treatment with any of the following: antipsychotics, isoniazid, centrally active antihypertensive drugs (e.g. clonidine, reserpine)\n* Metal in body or prior history working with metal fragments (e.g., as a machinist)\n* For women, pregnancy\n* Any other contraindications for MRI examination (e.g., metallic implants such as pacemakers, surgical aneurysm clips, or known metal fragments embedded in the body)\n* Claustrophobia",{"count":348,"type":22},[369],"EARLY_PHASE1","The current study probes the involvement of the opioid system in placebo effects on social pain, using the opioid antagonist naloxone. 60 participants who recently experienced an unwanted breakup will experience rejection-related stimuli and receive painful heat and pressure stimuli during fMRI scanning. Participants will be randomized to receive either a naloxone or saline nasal spray, and be informed that the spray is either saline, or an effective pain and negative emotion reducing agent.",[120,372,116],"Rejection",{"date":355,"type":45},{"date":204,"type":22},{"date":376,"type":22},"2027-03-01",{"name":50,"class":51},{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":100},"100408630","improving-implementation-of-evidence-based-approaches-and-surveillance-to-prevent-bacterial-transmission-and-infection-100408630","NCT04600973","Improving Implementation of Evidence-based Approaches and Surveillance to Prevent Bacterial Transmission and Infection","The BASIC Trial: Improving Implementation of Evidence-based Approaches and Surveillance to Prevent Bacterial Transmission and Infection","BASIC","Site Inclusion and Exclusion Criteria.\n\n* 250 patients (125 case pairs) per site in the active phase (N=3,000)\n* 250 patients (125 case pairs) per site in the sustainability phase (N=3,000)\n* Total N=6,000\n* orthopedic total joint and spine procedures\n\nSite Inclusion Criteria:\n\n* operating room conducting orthopedic total joint and spine\n* Surgeons performing orthopedic total joint or spine\n\nSite Exclusion Criteria:\n\n\\- medical centers actively enrolling patients in a bacterial transmission or infection prevention trial\n\nPatient Inclusion Criteria:\n\n\\- all elective patients undergoing orthopedic total joint and spine\n\nExclusion Criteria:\n\n* no requirement for anesthesia and\u002For placement of a peripheral intravenous catheter\n* lack of incision or informed, written consent\n* an allergy to chlorhexidine\n* povidone iodine or isopropyl alcohol\n* ASA health classification status\\>5",{"count":387,"type":22},6000,[25],"Surgical site infections (SSIs) are associated with increased patient morbidity, mortality, and healthcare costs. ESKAPE (Enterococcus, S. aureus, Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter spp.) pathogens are particularly pathogenic because they have increased capacity to acquire resistance and virulence traits. The investigators have proven that a multifaceted program involving improved basic perioperative preventive measures can generate substantial reductions in S. aureus transmission and significant reductions in SSIs (88% reduction as compared to usual care). In this study, the investigators aim to examine the relative effectiveness of each component of this program in controlling ESKAPE transmission and reducing SSIs and to identify an optimal implementation strategy for national dissemination. Randomization occurs at the site level, and sites adopt preventative programs. This work will improve perioperative patient safety for the 51 million patients who undergo surgery each year.",[391],"Infection",[393,394,395],"transmission","ESKAPE","prevention",{"date":397,"type":45},"2025-12-03",{"date":399,"type":45},"2021-07-01",{"date":401,"type":22},"2026-06-30",{"name":50,"class":51},{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":412,"briefSummary":413,"conditions":414,"keywords":417,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":52},"100591876","virtual-contexts-for-affective-modulation-100591876","NCT06986122","Virtual Contexts for Affective Modulation","Controllability of Virtual Contexts for the Modulation of the Affective Experience","VCAM","* No self-reported current or history of depression, bipolar disorder, or other psychiatric diagnosis\n* No self-reported current seizure disorder (i.e., seizure within past 10 years), or history of stroke or other major neurological diagnosis\n* No self-reported current chronic pain, or acute pain within three months of the study period\n* No current migraine disorder (i.e., 15 headache days or more in 1 month)\n* No use of central nervous system-effective medication or other medication for neurological\u002Fpsychiatric treatment\n* No self-reported substance abuse within the last six months\n* No contraindication to MRI (e.g., pregnancy, claustrophobia, pacemakers, ear\u002Fcochlear implants, shrapnel injuries, clips, or other ferromagnetic\u002Felectrical objects\u002Fdevices, diagnosed brain abnormality such as tumor, or skin lesions on the scalp.)\n* No contraindications for induced pain (e.g., no heart disease, high blood pressure, heart surgery, heart problems of any kind, severe asthma, respiratory problems of any kind, fibromyalgia, Raynaud's Syndrome or Disease, chronic pain, diabetes)\n* Participants must be capable of performing experimental tasks (e.g., are able to read), are fluent or native speakers of English\n* Participants must be able to tolerate the maximum level of thermal pain stimuli (for thermal stimuli)",{"count":5,"type":22},[25],"This study investigates how spatial context and perceived controllability modulate pain, affective states such as anxiety, and motivated behavior. The study examines how control over pain and threat-related environments influences pain perception, state anxiety, associated autonomic responses, and behavior. The main questions it aims to answer are:\n\nDoes having control over pain within specific contexts alter how much pain people feel-even when the stimulus intensity remains constant? How do different types of environments (safe, controllable, or uncontrollable) shape pain-related brain activity, subjective anxiety, and physiological arousal? How do people perform cognitively demanding or distracting tasks (and retain their memory) when under threat versus when in control? Lastly, how do these learned associations with spatial contexts persist or adapt when environmental contingencies are explicitly changed?\n\nTaken together, exploration of these factors may lay the groundwork for understanding how placebo-related mechanisms-including perceived control, contextual learning, emotional engagement, and distraction-interact to shape pain and anxiety in complex environments.",[415,142,416],"Pain Control","Memory",[418,419],"Place conditioning","controllability of pain","2025-10-29",{"date":422,"type":45},"2025-10-31",{"date":424,"type":45},"2025-10-28",{"date":426,"type":22},"2029-06-15",{"name":50,"class":51},{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":23,"phases":437,"briefSummary":439,"conditions":440,"keywords":444,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":52},"100586811","phase-1-use-of-a-generative-ai-gen-ai-chatbot-for-anxiety-and-depression-among-persons-with-cannabis-use-100586811","NCT06920238","Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use","A Phase I Single-Arm Trial to Test the Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use Disorder (CUD)","Inclusion Criteria:\n\n* Is 18 years or older.\n* Meet criteria for current CUD (CUDIT-R\\>=12) and MDD (PHQ-9\\>=10), and\u002For GAD (GAD-7\\>=10).\n* Have reliable access to the internet and a compatible device for Therabot-CALM.\n* Have willingness and capacity to provide informed consent and commit to participating in all assessments and interventions during the study.\n* Attend the first interview.\n\nExclusion Criteria:\n\n* Moderate to High risk of STBs as determined by the C-SSRS or baseline questionnaires.\n* Current psychosis (as determined by brief psychosis screen).\n* Current participation in another digital mental health intervention.",{"count":436,"type":22},15,[438],"PHASE1","The goal of this clinical trial is to learn if Therabot-CALM (Cannabis, Anxiety, Low Mood) has acceptability among users and could work to improve the symptoms of persons with cannabis use disorder and anxiety and\u002For depression. The main question it aims to answer is:\n\nWhat is the usability, feasibility, and acceptability of Therabot-CALM in persons with Cannabis Use Disorder and Anxiety and\u002For Depression?\n\nParticipants will\n\n* Take a screening questionnaire\n* Participate in two virtual 1-hour interviews to provide feedback on app design and suggest features.\n* Engage with Therabot-CALM in a 4-week clinical trial and provide feedback on their app experience in a third virtual interview",[441,142,442,443],"Cannabis Use Disorder","Depression, Anxiety","Depression - Major Depressive Disorder",[445,446,447,448,449,441,142,143,450,144,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467],"Artifical Intelligence","Generative AI","Generative Artificial Intelligence","Therabot","Therabot-CALM","Chatbot","Drug Abuse","Drug Use","Drug Use Disorder","Interview","Screening","Application","REDCap","post-intervention measures","System Usability Scale","Treatment Acceptability and Adherence Scale","Cannabis Use Disorders Identification Test - Revised","Cannabis Use Disorders Identification Test","Quantity of Cannabis Use Inventory","Patient Health Questionnaire for depression","generalized anxiety disorder screener","DSM-5","Zoom","2025-09-05",{"date":470,"type":45},"2025-09-08",{"date":472,"type":45},"2025-04-13",{"date":474,"type":22},"2025-12",{"name":50,"class":51},{"id":477,"slug":478,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":482,"targetDuration":4,"studyType":23,"phases":483,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":492,"leadSponsor":494,"locationsCount":52},"100601254","interactions-between-placebo-effects-and-mindful-awareness-state-100601254","NCT07108101","Interactions Between Placebo Effects and Mindful Awareness State","* No self-reported current or history of depression, bipolar disorder, or other psychiatric diagnosis\n* No self-reported current seizure disorder (i.e., seizure within past 10 years), or history of stroke or other major neurological diagnosis that can cause cognitive impairment\n* No self-reported current chronic pain, or acute pain within three months of the study period\n* No current migraine disorder (i.e., 15 headache days or more in 1 month)\n* No use of central nervous system-effective medication or other medication for neurological\u002Fpsychiatric treatment\n* No self-reported substance abuse within the last six months\n* No contraindication to MRI or tDCS (e.g., pregnancy, claustrophobia, pacemakers, ear\u002Fcochlear implants, shrapnel injuries, clips, or other ferromagnetic\u002Felectrical objects\u002Fdevices, diagnosed brain abnormality such as tumor, or skin lesions on the scalp.)\n* No contraindications for induced pain (e.g., no heart disease, high blood pressure, heart surgery, heart problems of any kind, severe asthma, respiratory problems of any kind, fibromyalgia, Raynaud's Syndrome or Disease, chronic pain, diabetes)\n* Participants must be capable of performing experimental tasks (e.g., are able to read), are fluent or native speakers of English\n* Participants must be able to tolerate the maximum level of thermal pain stimuli (for thermal stimuli)",{"count":304,"type":22},[25],"In this experiment,the investigators study the effects of interpersonally induced placebo effects and a mindful awareness induction on negative affect. Specifically, it will be examining the effects of interpersonally induced placebo effects (sham tDCS vs. control) and a mindful awareness induction (mindful state vs. control), as well as their interaction. Each group will undergo fMRI scanning and physiological recording will performing the Multimodal Negative Affect Task (MNAT).",[116,486,120,487],"Mindfulness","Transcranial Direct Current Stimulation (tDCS)","2025-07-31",{"date":490,"type":45},"2025-08-06",{"date":96,"type":22},{"date":493,"type":22},"2028-11-30",{"name":50,"class":51},{"id":496,"slug":497,"hasResults":11,"nctId":498,"briefTitle":499,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":107,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":502,"targetDuration":4,"studyType":23,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":52},"100592155","transcranial-direct-current-stimulation-and-modulation-of-affect-and-pain-100592155","NCT06989749","Transcranial Direct Current Stimulation and Modulation of Affect and Pain","StimMAP","Inclusion Criteria:\n\n* ages 18-55\n* Participants must be capable of performing experimental tasks (e.g., are able to read)\n* Fluent or native speakers of English\n\nExclusion Criteria:\n\n* No self-reported current or history of depression, bipolar disorder, or other psychiatric diagnosis.\n* No self-reported current seizure disorder (i.e., seizure within past 10 years)\n* No history of stroke or other major neurological diagnosis.\n* No self-reported current chronic pain, or acute pain within three months of the study period.\n* No current migraine disorder (i.e., 15 headache days or more in 1 month).\n* No use of central nervous system-effective medication or other medication for neurological\u002Fpsychiatric treatment. No self-reported substance abuse within the last six months.\n* No contraindication to MRI or tDCS (e.g., pregnancy, claustrophobia, pacemakers, ear\u002Fcochlear implants, shrapnel injuries, clips, or other ferromagnetic\u002Felectrical objects\u002Fdevices, diagnosed brain abnormality such as tumor, or skin lesions on the scalp.).\n* No contraindications for induced pain (e.g., no heart disease, high blood pressure, heart surgery, heart problems of any kind, severe asthma, respiratory problems of any kind, fibromyalgia, Raynaud's Syndrome or Disease, chronic pain, diabetes).",{"count":218,"type":22},[25],"This double-blind randomized crossover study aims to examine the effects of left primary motor cortex (M1) tDCS on evoked thermal pain perception, pain-related decision making, and placebo effects by manipulated pain and monetary offers accepted by others. The investigators plan to collect data for up to 50 participants who undergo four separate sessions: an initial pain calibration session and three experimental sessions with either anodal, cathodal, or sham tDCS. Each session includes pain testing before and after a single tDCS protocol (either anodal, cathodal, or sham), a pain-monetary decision-making task, and social placebo pain tests. All tasks following tDCS will take place inside the MR scanner. The investigators hypothesize that anodal M1 tDCS will decrease pain ratings, and that cathodal tDCS will increase them, both relative to the sham condition. The investigators will also examine the effects of M1 tDCS on social decision-making to examine whether it affects participants' valuation of pain and their altruistic behavior, as well as how these same factors impact pain sensation in the placebo task. The investigators hypothesize that participants will behave hyperaltruistically during the decision-making task, and that the same factors that influence choice will also impact pain perception in the same context.",[506],"We Are Not Studying a Disease or Condition",[508,509,510,511],"transcranial direct current stimulation","experimental pain","pain-related decision-making","social placebo effects","2025-05-22",{"date":514,"type":45},"2025-05-25",{"date":516,"type":45},"2023-09-09",{"date":518,"type":22},"2026-09",{"name":50,"class":51},{"id":521,"slug":522,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":107,"sex":17,"minAge":527,"maxAge":528,"enrollmentInfo":529,"targetDuration":4,"studyType":23,"phases":531,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":52},"100557163","genetic-risk-parental-feeding-practices-and-appetitive-traits-in-early-life-100557163","NCT06534541","Genetic Risk, Parental Feeding Practices, and Appetitive Traits in Early Life","Characterizing the Relationships of Genetic Risk and Parental Coercive Feeding Practices With Appetitive Traits and Adiposity Gain Across Early Life.","Inclusion Criteria:\n\n* parent must be ≥18 years old, have primary custody of their child for ≥75% of the month, comprehend verbal and written English and not plan to move out of Vermont or New Hampshire during the study timeframe.\n* Children must be ≥2.25 and ≤2.99 years old at first visit and have normal or corrected-to-normal vision to enable eye tracking.\n\nExclusion Criteria:\n\n* Children with any relevant food allergies or dietary restrictions, taking medication or with a medical condition that affects appetite or attention, or with a relative enrolled in the study will be excluded.","27 Months","72 Months",{"count":530,"type":22},330,[25],"The preschool years (2-5 years of age) is a critical timeframe to shape the lifetime risk of obesity. While the causes of obesity are complex, appetitive traits related to overeating, such as high food approach and low food avoidance, are robustly associated with a greater BMI among children. Some children are genetically pre-disposed to expressing obesogenic appetitive traits, and those traits may mediate a genetic risk for obesity. Separately, parental feeding practices are emerging as an important, yet modifiable, influence on children's obesity risk. Coercive control feeding practices, such as strictly limiting a child's intake of highly palatable foods (restriction) and using food to control children's negative emotions (emotional feeding), are believed to be detrimental for young children because they impede self-regulatory skills around eating and may increase the saliency of highly palatable foods. The goal for this project is to disentangle the inter-relationships between coercive control feeding practices, children's obesogenic appetitive traits, and children's dietary intake across the preschool years to understand how coercive control feeding practices ultimately impact children's adiposity gain over time. Importantly, the investigators aim to understand how those effects differ based on children's underlying genetic risk for obesity. The investigators hypothesize that parents will respond to children's obesogenic appetitive traits by exhibiting more coercive control feeding practices (restriction, emotional feeding), which in turn, will promote future increase in obesogenic appetitive traits and overconsumption, leading to excess adiposity gain among children. Importantly, the investigators hypothesize children with a high genetic risk for obesity will be most susceptible to the negative effects of coercive control feeding practices because food is highly salient for them. The investigators will test the hypotheses among a cohort of children aged 2.5 years old using a longitudinal study design with repeated assessments every 6 months until children are 5 years old. If successful, study findings may be leveraged to develop tailored strategies to help parents support healthy eating behaviors among their young children that consider the heterogeneity in obesogenic appetitive traits among young children due to genetic risk factors.",[534],"Childhood Obesity","2025-03-21",{"date":537,"type":45},"2025-03-26",{"date":539,"type":45},"2024-07-18",{"date":541,"type":22},"2029-08",{"name":50,"class":51},""]